1. Companies

  2. Theranexus

Theranexus

Theranexus

Developing drug combinations that consist of one compound that targets neurons and another that modulates the activity of astrocytes.
Launch date
Employees
11-50 people
Market cap
AUD7.9m
Enterprise valuation
AUD6m (Public information from Sep 2024)
Company register number 791889777
Lyon Auvergne-Rhône-Alpes (HQ)
https://www.theranexus.com/fr/
https://twitter.com/theranexushttps://www.linkedin.com/company/theranexus/

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2019202020212022202320242025
EBITDA(7.4m)(5.5m)(8.7m)(6.1m)(7.3m)(6.9m)(6.9m)
Profit(5.6m)(4.8m)(8.2m)(6.6m)(6.8m)(7.3m)(7.1m)
EV / EBITDA-0.6x-11.6x-1.8x-0.8x-1.0x-2.8x-3.8x
    • Edit
DateInvestorsAmountRound
-

N/A

-

N/A

Spinout

€3.6m

Seed
*
N/A

€20.4m

Valuation: €48.4m

IPO
N/A

€2.2m

Post IPO Equity
*

N/A

Early VC
Total FundingAUD6.1m

Recent News about Theranexus

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.